November 2, 2009 — (BRONX, NY) — Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.
The original study — the Diabetes Prevention Program (DPP) — was a large, randomized trial involving 3,234 people at high risk for developing diabetes. All participants were overweight or obese adults with elevated blood glucose levels when the study began. At the time of the DPP study, Allen M. Spiegel, M.D., the Marilyn and Stanley M. Katz Dean of Einstein, was director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), one of 27 institutes and centers of the National Institutes of Health. In 2001, he made the decision to stop the multicenter study a year earlier than scheduled — at Einstein and 25 other sites nationwide — because results were so convincing. After three years, intensive lifestyle changes (modest weight loss coupled with increased physical activity) had reduced the rate for developing type 2 diabetes by 58 percent compared with placebo. The oral diabetes drug metformin (850 milligrams twice daily) had reduced the rate of developing diabetes by 31 percent compared with placebo.
At that time, Dr. Spiegel noted, "Every year a person can live free of diabetes means an added year of life free of the pain, disability, and medical costs incurred by this disease. The DPP findings represent a major step toward the goal of containing and ultimately reversing the epidemic of type 2 diabetes in this country."
Since these striking results from the DPP study were based on just three years of data, researchers could not determine how long the benefits would last. Following a seven-month bridge period after the original study ended, the follow-up DPPOS began, with 88 percent of DPP volunteers taking part. During the study pause, all participants learned the results and were offered 16 education sessions on making intensive lifestyle changes. The latest results, reflecting a full decade of participation â”€ three in the DPP study and seven in DPPOS — indicate that lifestyle interventions producing even modest weight loss can significantly help to prevent or delay diabetes over the long term.
Specifically, for the 10 years spanning the DPP and DPPOS studies, the diabetes incidence (i.e., rate at which new diabetes cases were diagnosed) in the lifestyle group was reduced by 34 percent compared with placebo. For the group taking the diabetes drug metformin, diabetes incidence was reduced by 18 percent. Expressed another way, the lifestyle group delayed type 2 diabetes by about four years compared with placebo, and the metformin group delayed it by two years.
"The fact that we've continued to delay and possibly even prevent diabetes in people at very high risk for developing the disease is certainly a positive finding."
-- Jill Crandall, M.D."The fact that we've continued to delay and possibly even prevent diabetes in people at very high risk for developing the disease is certainly a positive finding," says Dr. Crandall. She notes that those people randomly assigned to make lifestyle changes also had more favorable cardiovascular risk factors (including lower blood pressure and triglyceride levels) despite a reduction in drug treatment prescribed by their personal physicians.
The benefits of intensive lifestyle changes were especially pronounced among older people. Those aged 60 and over lowered their rate of developing type 2 diabetes in the next 10 years by about half.
The increase in the number of overweight Americans has led to an epidemic of type 2 diabetes that shows no signs of slowing. More than two-thirds of adults are now overweight or obese. About 11 percent of adultsâ”€24 million peopleâ”€have diabetes, and up to 95 percent of them have type 2 diabetes, according to the National Institutes of Health. Diabetes is a major cause of heart disease and stroke and the major cause of kidney failure, limb amputations and new-onset blindness.
The researchers are now analyzing the DPPOS data to see whether clinical outcomes differ among the three groups. "The long-term weight loss and reduction in diabetes that we observed in DPPOS are encouraging," says Dr. Crandall. "But ultimately, establishing the benefits of preventing diabetes means showing that you can reduce the deaths and the severe complications associated with this disease."
The study, "10-year Follow-up of Diabetes Incidence and Weight Loss in the Diabetes Prevention Program Outcomes Study," appears in the October 29, 2009 online edition of The Lancet. In addition to Dr. Crandall, other Einstein researchers involved in DPPOS were Harry Shamoon, M.D., Elizabeth Walker, Ph.D., Judith Wylie-Rosett, Ed. D., Swapnil Rajpathak, M.B.B.S, Dr. P.H., and Janet Brown-Friday, R.N., M.P.H.